eTheRNA: New agreement paves way for development of first African-owned COVID-19 vaccine

A year after the establishment of the mRNA Vaccine Technology Transfer Hub, Afrigen and Univercells enter a new agreement to develop the first African-own COVID-19 vaccine

 CAPE TOWN (SOUTH AFRICA) & BRUSSELS (BELGIUM), JUNE 21, 2022 – One year since the establishment of the mRNA Vaccine Technology Transfer Hub, a collaboration between two of the world’s leading biotech companies – Afrigen Biologics and the Univercells Group – was announced today. This agreement intends to pave the way for the development of the first-ever African-owned COVID-19 vaccine. The collaboration will focus on the development of a novel mRNA vaccine using intellectual property from the collaboration partners, as well as developing new IP, and is intended to supercharge access to the vaccine. Afrigen and Univercells will be supported in the collaboration by mRNA specialist eTheRNA.

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH